Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaustauf – page 24

349 clinical trials in Donaustauf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaustauf at a glance
349
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

349 trials in Donaustauf

Open in trial search

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma GmbH

Study on the Effects of Dexamethasone in Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaustauf

What the registry says about research in the country

01 Pulmonary Research

Clinical investigations focusing on idiopathic pulmonary fibrosis (IPF), a progressive lung condition that affects respiratory function. These trials aim to evaluate new therapeutic approaches for improving lung function in affected patients.

  • Respiratory Function Assessment
  • Treatment Response Evaluation
  • Dose-Response Analysis

Research efforts include comparative studies between various treatment doses and placebo to determine optimal therapeutic effectiveness for patients with pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.